Long Course Adjuvant Chemotherapy — Competitive Intelligence Brief

Long Course Adjuvant Chemotherapy (Long Course Adjuvant Chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen. Area: Oncology.

phase 3 Chemotherapy regimen Oncology Small molecule

Target snapshot

Long Course Adjuvant Chemotherapy (Long Course Adjuvant Chemotherapy) — Trans Tasman Radiation Oncology Group. Long course adjuvant chemotherapy delivers extended cycles of cytotoxic chemotherapy after primary cancer treatment to eliminate residual disease and reduce recurrence risk.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Long Course Adjuvant Chemotherapy TARGET	Long Course Adjuvant Chemotherapy	Trans Tasman Radiation Oncology Group	phase 3	Chemotherapy regimen
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
FEC	FEC	Hoffmann-La Roche	marketed	Combination chemotherapy regimen
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)
TCH chemotherapy	TCH chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)	HER2, microtubule, DNA
CVP	CVP	SCRI Development Innovations, LLC	marketed	Combination chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen class)

1. National Research Center for Hematology, Russia · 2 drugs in this class
2. Asan Medical Center · 1 drug in this class
3. AstraZeneca · 1 drug in this class
4. CTI BioPharma · 1 drug in this class
5. Federation Francophone de Cancerologie Digestive · 1 drug in this class
6. Guiyang Medical University · 1 drug in this class
7. Japan Clinical Oncology Group · 1 drug in this class
8. PETHEMA Foundation · 1 drug in this class
9. Sixth Affiliated Hospital, Sun Yat-sen University · 1 drug in this class
10. Trans Tasman Radiation Oncology Group · 1 drug in this class